NCT06510309
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma treatment 2 not_yet_recruiting NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 withdrawn NCT03797456
A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) No drug interventions treatment 2 completed NCT03846427
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma treatment 2 completed NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT00877214
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas treatment 3 active_not_recruiting NCT00991211
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab treatment 3 completed NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT06149286
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma treatment 3 recruiting NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T No drug interventions other 1 enrolling_by_invitation NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML treatment 1 recruiting NCT03265158
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 No drug interventions Not Available Not Available unknown_status NCT04796922
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) treatment 3 withdrawn NCT06043011
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms No drug interventions Not Available Not Available recruiting NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma treatment 1 / 2 active_not_recruiting NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT03869619
REal World Data in LYmphoma and Survival in Adults No drug interventions Not Available Not Available recruiting NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT04431089
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma No drug interventions treatment 2 unknown_status NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment Not Available Not Available completed NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No drug interventions treatment 1 completed NCT00085696
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma treatment 2 completed NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) treatment 1 completed NCT03682796
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma No drug interventions treatment 1 completed NCT04735471
A Phase 1 Study of ADI-001 in B Cell Malignancies treatment 1 active_not_recruiting NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma treatment 3 recruiting NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL No drug interventions treatment 1 recruiting NCT03028103
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients treatment 1 completed NCT02927964
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma treatment 1 / 2 completed NCT01460602
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma treatment 1 / 2 withdrawn NCT04792502
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma treatment 2 recruiting NCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) Not Available Not Available not_yet_recruiting NCT01306643
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma treatment 1 / 2 completed NCT04849351
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma No drug interventions treatment 2 recruiting NCT01000753
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma No drug interventions Not Available Not Available completed NCT04508647
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma treatment 2 completed NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. No drug interventions treatment 1 recruiting NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers treatment 1 / 2 terminated NCT04043845
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies treatment 1 withdrawn NCT03884998
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases treatment 2 recruiting NCT03768505
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) treatment 2 terminated NCT04279405
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies No drug interventions treatment 1 completed NCT05934097
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma treatment 1 withdrawn NCT02793583
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma treatment 2 / 3 terminated NCT01980628
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma treatment 2 completed NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans No drug interventions Not Available Not Available not_yet_recruiting NCT06390956
Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma treatment 2 not_yet_recruiting NCT00901615
Lenalidomide and R-CHOP in B-cell Lymphoma treatment 1 / 2 completed NCT04665115
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) treatment 2 withdrawn NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia treatment 1 completed NCT06340737
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas No drug interventions treatment 1 recruiting NCT04745832
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) treatment 3 terminated NCT03269552
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma treatment 2 terminated NCT04680052
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. treatment 3 active_not_recruiting NCT04189952
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma treatment 2 terminated NCT00337259
Gemcitabine for Marginal Zone Lymphoma treatment 2 terminated NCT03919175
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma treatment 2 terminated NCT01239875
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma treatment 0 completed NCT05296070
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma treatment 2 recruiting NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT04082936
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT04212013
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma treatment 3 active_not_recruiting NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas treatment 2 recruiting NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab treatment 1 / 2 active_not_recruiting NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma treatment 1 recruiting NCT05003141
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies No drug interventions treatment 1 unknown_status NCT06006117
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma treatment 3 recruiting NCT06513234
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas treatment 2 recruiting NCT04599634
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies treatment 1 completed NCT04333524
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role No drug interventions Not Available Not Available recruiting NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas treatment 1 / 2 terminated NCT05169658
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma treatment 2 recruiting NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT06151730
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study No drug interventions Not Available Not Available recruiting NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies treatment 1 recruiting NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) treatment 1 active_not_recruiting NCT01121757
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma treatment 2 terminated NCT03322865
Obinutuzumab in Marginal Zone Lymphoma treatment 2 active_not_recruiting NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT03520920
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) treatment 2 completed NCT03010982
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors treatment 1 completed NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) treatment 1 completed NCT03474744
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients treatment 2 active_not_recruiting NCT06504940
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) treatment 2 recruiting NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT03276468
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas treatment 2 completed NCT03697512
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas treatment 2 active_not_recruiting NCT01314014
Imexon for Relapsed Follicular and Aggressive Lymphomas treatment 2 completed NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia treatment 2 recruiting NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation treatment 2 active_not_recruiting NCT00453102
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma treatment 2 completed NCT06424379
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. No drug interventions Not Available Not Available active_not_recruiting NCT04416451
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma treatment 2 active_not_recruiting NCT04268277
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY treatment Not Available recruiting NCT05907447
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types No drug interventions Not Available Not Available not_yet_recruiting NCT02242045
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) treatment 1 completed NCT06125028
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma other 3 recruiting NCT05653271
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies treatment 1 recruiting NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT04669171
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma treatment 1 / 2 recruiting NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies treatment 1 / 2 active_not_recruiting NCT04911478
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells No drug interventions Not Available Not Available enrolling_by_invitation NCT01728207
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL treatment 1 terminated NCT06566807
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma treatment 2 recruiting NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT05107856
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies treatment 1 terminated NCT04433156
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma treatment 2 recruiting NCT06449885
A Cohort Study in Newly Diagnosed MZL No drug interventions Not Available Not Available recruiting NCT00880815
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant treatment 1 completed NCT04883437
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas treatment 2 recruiting NCT04116437
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment treatment 2 recruiting NCT04464200
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers No drug interventions treatment 1 active_not_recruiting NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant supportive_care 2 completed NCT02576275
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) treatment 3 withdrawn NCT04491370
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma treatment 1 / 2 recruiting NCT03105336
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma treatment 2 active_not_recruiting NCT01282424
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas treatment 2 completed NCT04542824
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL treatment 1 / 2 active_not_recruiting NCT05783596
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma treatment 2 recruiting NCT03010358
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT06534463
Registry Study of Chinese Patients With Marginal Zone Lymphoma (MOTIVE) No drug interventions Not Available Not Available not_yet_recruiting NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma treatment 2 active_not_recruiting NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies treatment 1 not_yet_recruiting NCT04952974
B-cell Chronic Lymphoid Malignancies Markers No drug interventions Not Available Not Available unknown_status NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma treatment 2 withdrawn NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients prevention 2 terminated NCT03364231
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma treatment 2 completed NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader No drug interventions treatment 1 / 2 recruiting NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine treatment 1 active_not_recruiting NCT01239394
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma treatment 2 completed NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL treatment 1 / 2 active_not_recruiting NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas treatment 1 active_not_recruiting NCT06478472
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy treatment Not Available recruiting NCT06454968
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. treatment 2 recruiting NCT00772668
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL treatment Not Available terminated NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies treatment 1 terminated NCT03498612
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases treatment 2 active_not_recruiting NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies treatment 1 / 2 completed NCT00801281
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. treatment 3 completed NCT04646395
Study of Acalabrutinib and Tafasitamab in MZL Patients treatment 2 active_not_recruiting NCT02258555
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma No drug interventions treatment 1 terminated NCT03078855
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma supportive_care 3 completed NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies treatment 1 completed NCT05846750
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma treatment 2 recruiting NCT05326308
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma Not Available Not Available recruiting NCT01500538
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) treatment 2 terminated